PediaMed Clinical Trials | Home  Sitemap  Contact
Skip Navigation Links
Home
Pipeline
Products
News
Investors
Biz Dev
Careers
About


February 22, 2006
PediaMed Successfully Completes Clinical Trial Enrollment to Study New Therapy In Children with Autism

 

Management

PediaMed Management Team

Thomas P. Jennings, President & Chief Operating Officer Dr. Jon Bruss, Vice President & Chief Medical Officer
Martin P Manco, Vice President, Business Development & Manufacturing Operations Dr. Avi Kometz, Head, Corporate Development

PediaMed Board of Directors

Roger Griggs, Executive Chairman
John C. McIlwraith James L. Currie

Roger D. Griggs
Executive Chairman
Mr. Roger D. Griggs is a successful entrepreneur and businessman who serves as Chairman of the Board for PediaMed Pharmaceuticals, Inc. Roger has founded numerous businesses throughout his career, including Union Springs, LLC (investment organization), Richwood Pharmaceuticals (currently Shire Pharmaceuticals), Integrity Pharmaceuticals, Xanodyne Pharmaceuticals, and DECA (Drug Enhancement Corporation of America). He currently serves on the boards of several companies, including those listed above.

Prior to founding PediaMed Pharmaceuticals, Inc., Roger's accomplishments include his and Kathy Griggs's creation of Richwood Pharmaceutical Company, Inc. in 1990. The company was founded to license, market, and distribute ethical pharmaceutical products in Central Nervous System (CNS)-focused markets. In 1997, Richwood merged with Shire Pharmaceutical Group PLC to create Shire-Richwood Inc. The company is listed on both the London and NASDAQ stock exchanges and has a valuation in excess of $5 billion.

Roger began his career as a teacher and football coach, eventually coaching at the high school and intercollegiate levels. His pharmaceutical career began in 1981, when he joined Lederle Laboratories (now American Home) as a field sales representative. His outstanding sales record resulted in numerous promotions, eventually leading to a District Sales Manager position. He left Lederle in 1988 to accept a position with Russ Pharmaceutical Company (currently UCB Pharma) as National Director for Institutional Sales. Under Roger's direction, the Northern Region increased sales from less than $1 million in 1988 to more than $4.9 million in 1990.

Roger holds a Bachelor's of Science degree in Secondary Education from Indiana University and a Master's of Science degree from Indiana University at South Bend.


Thomas P. Jennings, JD, CPA
President & Chief Operating Officer

Mr. Thomas P. Jennings is President of Union Springs, LLC, a private equity company focused on starting and growing branded niche pharmaceutical companies. Union Springs provides funding, strategic planning and business development and legal assistance to all of its companies. Since 1998, Union Springs and its investors have founded PediaMed Pharmaceuticals Inc. (infants, children), Xanodyne Pharmaceuticals, Inc. (cancer, pain management) and Integrity Pharmaceuticals Inc. (women’s health, urology). In 2003, Union Springs plans to expand to include two new companies focused on ethnic health and drug development.

Prior to joining Union Springs, LLC, Tom was in private law practice, where the primary focus was mergers and acquisitions and tax related issues. Prior to that, Tom was a CPA with Ernst & Young.

Tom is a graduate of the Salmon P. Chase College of Law and also holds a B.B.A. in Accounting from the University of Cincinnati.


Dr. Jon Bruss, MD, MSPH, MBA
Vice President & Chief Medical Officer

Dr. Bruss is a board certified pediatrician with experience in clinical pediatrics, public health management, and broad experience in anti-infective and biologics drug development (Phases I-IV). He has a broad understanding of principles of scientific research and the commercialization of medicines for children.

Jon has successfully registered drugs in the US, Europe, and Japan, including negotiations with regulatory authorities in these countries. He has experience with full pediatric development programs including complex studies in neonates.

Jon received his MD from the University of New Mexico and then completed a pediatric residency at the Children’s Hospital of New Mexico. He completed a fellowship in pediatric infectious diseases at Harvard Medical School and Boston Children’s Hospital and remained on faculty conducting vaccine related research. He received a MSPH degree at Tulane University, School of Public Health and a MBA degree at Kellogg School of Business Management, Northwestern University.


Martin P. Manco, MBA, JD
Vice President Business Development & Manufacturing Operations

For over 20 years Mr. Manco has managed early stage ventures, as attorney, consultant, CFO, and CEO. He has worked in pharmaceuticals, clinical diagnostics, bio-safety laboratories, microbiological quality assurance, and a variety of manufacturing and service sectors.

Martin was also Lecturer at The Pennsylvania State University and taught in the Graduate Program in Management. His work at Penn State focused on entrepreneurship, knowledge management, and ethics. He is a member of the Pennsylvania Bar Association, the Institute of Management Accountants, and the Knowledge Management Group of Philadelphia.

Martin holds an undergraduate degree from The Wharton School of the University of Pennsylvania, a Masters in Business Administration and Advanced Certificate in MIS from Penn State, and his J.D. from The Widener University Law School. He is an attorney and a Certified Management Accountant.


Avi Kometz, MD
Head, Corporate Development

Dr. Kometz brings a wealth of experience in pharmaceutical company valuation and development and practical experience in pediatric healthcare. He joined PediaMed from McKinsey and Company, a leading management consultancy firm, where he was engaged in pharmaceutical company pipeline valuation and corporate development.

Prior to working as a McKinsey consultant, Avi developed a medical practice serving more than 4,000 patients in South Africa. He later would go on to establish a medical center comprising five clinics throughout South Africa.

Avi earned his bachelor of medicine and bachelor of surgery degree from the University of Witwatersrand, Medical School in Johannesburg, South Africa and served a twelve month clinical internship at Baragwanath Hospital in Soweto, Africa.


John C. McIlwraith
Board of Directors

Prior to joining Blue Chip in 1997, Mr. McIlwraith was the Senior Vice President of Strategic Planning for Quantum Health Resources, where he led business development efforts including new drug launches and managed care initiatives. Prior to Quantum, John was a Partner with Jones Day Reavis & Pogue and led the Firm’s Venture Capital Practice Group. While at Jones Day, John represented firms such as Morgenthaler Venture Partners and Primus Venture Partners, as well as a number of early stage companies.

John is on the Board of Advisors for Arbor Partners, Isabella Capital, Ohio Innovation Fund, and is part of the Executive Committee for Gazelle TechVentures.

John has a Bachelor of Arts degree from Hillsdale College, and a Juris Doctor degree, magna cum laude, from Case Western Reserve University School of Law.


James L. Currie
Board of Directors
Mr. Currie has been involved in healthcare ventures for more than 30 years as an investment banker, entrepreneur, and venture capitalist. He began his career in investment banking at Evans & Co., and Laird & Co., both of which specialized in emerging companies. In 1972, he co-founded Munger, Baker and Currie, Inc., a boutique investment that specialized in IPOs and private placement. In 1977, he led the leveraged buyout and subsequently ran Central Scientific, Inc., a healthcare-focused laboratory equipment company, which he successfully sold in 1984. During his tenure at Central Scientific, he played key roles in the financing of Critical Care of America and LyphoMed, two of the most successful healthcare companies in the last 20 years.

In 1985, Jim founded Essex Venture Partners, which eventually became Essex Woodlands. As a venture capitalist, he has led the investment and development of numerous successful healthcare companies, including Allscripts Healthcare Solutions, Ethical Holdings, Parexel International, Richwood/Shire Pharmaceuticals, and Serologicals. Mr. Currie currently serves on the Board of Directors of Control Delivery Systems, InSound Medical, PediaMed Pharmaceuticals, Xanodyne Pharmacal, Integrity, SleepMed and Prism Pharmaceuticals.

Jim holds a Bachelor of Arts degree from Pennsylvania State University.